Results 241 to 250 of about 29,580 (292)

The Ongoing Challenges of Managing Cytopenic Myelofibrosis in 2025: The Emergence of Non-JAK Inhibitor Therapies. [PDF]

Blood Lymphat Cancer
Reynolds SB, Komrokji R, Kuykendall AT.
europepmc   +1 more source

Ruxolitinib and Hepatitis-B Virus Reactivation: A Clinical Concern Requiring Prophylactic Management

Ji Eun Park, Jieun Yang, Sang-Hoon Han
openalex   +1 more source

Long-term safety and effectiveness of ruxolitinib in patients with myelofibrosis in Japan: an observational study. [PDF]

Future Oncol
Aruga Y, Hongo W, Lu W.
europepmc   +1 more source

Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream

Khaled Ezzedine, Albert Wolkerstorfer, Shaoceng Wei, A. Amara Korba, Deanna Kornacki, David Rosmarin   +5 more
openalex   +2 more sources

The Mechanisms of Resistance to JAK Inhibitors in Lymphoid Leukemias: A Scoping Review of Evidence from Preclinical Models and Case Reports. [PDF]

Int J Mol Sci
Martínez Anaya D, Coyotecatl MV, Navarrete Meneses MDP, Enríquez Flores S, Pérez-Vera P.   +4 more
europepmc   +1 more source

Inflammatory mediators differentially regulate megakaryopoiesis and thrombopoiesis in myelofibrosis and essential thrombocythemia. [PDF]

Sci Rep
Yañuk DB, Cellucci AS, Marta RF, Discianni Lupi AD, De Luca G, Glembotsky AC, Rios MAC, Moiraghi B, Sackmann F, Guerrieri VC, Heller PG, Goette NP, Lev PR.   +12 more
europepmc   +1 more source

Network Meta-analysis of 1.5% Ruxolitinib Cream Versus Systemic Agents in the Treatment of Moderate Atopic Dermatitis. [PDF]

Dermatol Ther (Heidelb)
Gooderham MJ, Hong HC, Wang D, Hooper B, Hughes-Martin A, Cameron H, Pastor L, Pepper A, Wu P, Mojebi A, Wong G, Marino R, Dion ML, Larbi M.   +13 more
europepmc   +1 more source

Hyper-activation of STAT3 sustains progression of non-papillary basal-type bladder cancer via FOSL1 regulome [PDF]

, 2019
et al,, Vermi, William
core   +1 more source

Revised "iRR6" model in intermediate-1 risk myelofibrosis patients treated with ruxolitinib. [PDF]

Cancer
Palandri F, Branzanti F, Bonifacio M, Elli EM, Morsia E, Farina M, Tiribelli M, Benevolo G, Beggiato E, Martino B, Caocci G, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Abruzzese E, Isidori A, Dedola A, Scalzulli E, Duminuco A, Tosoni L, Strazimiri A, Lemoli RM, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT.   +31 more
europepmc   +1 more source

YAP-induced MAML1 cooperates with STAT3 to drive hepatocellular carcinoma progression. [PDF]

Exp Hematol Oncol
Li J, Li X, Wang R, Li M, Xiao Y.
europepmc   +1 more source